Stock Analysis
- Japan
- /
- Healthcare Services
- /
- TSE:2784
Alfresa Holdings Corporation's (TSE:2784) Price Is Right But Growth Is Lacking
When close to half the companies in Japan have price-to-earnings ratios (or "P/E's") above 14x, you may consider Alfresa Holdings Corporation (TSE:2784) as an attractive investment with its 10.9x P/E ratio. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/E.
Alfresa Holdings certainly has been doing a good job lately as it's been growing earnings more than most other companies. One possibility is that the P/E is low because investors think this strong earnings performance might be less impressive moving forward. If not, then existing shareholders have reason to be quite optimistic about the future direction of the share price.
View our latest analysis for Alfresa Holdings
Is There Any Growth For Alfresa Holdings?
The only time you'd be truly comfortable seeing a P/E as low as Alfresa Holdings' is when the company's growth is on track to lag the market.
Taking a look back first, we see that the company managed to grow earnings per share by a handy 13% last year. The latest three year period has also seen an excellent 65% overall rise in EPS, aided somewhat by its short-term performance. Accordingly, shareholders would have probably welcomed those medium-term rates of earnings growth.
Turning to the outlook, the next three years should bring diminished returns, with earnings decreasing 1.8% per annum as estimated by the three analysts watching the company. Meanwhile, the broader market is forecast to expand by 9.2% per year, which paints a poor picture.
In light of this, it's understandable that Alfresa Holdings' P/E would sit below the majority of other companies. Nonetheless, there's no guarantee the P/E has reached a floor yet with earnings going in reverse. There's potential for the P/E to fall to even lower levels if the company doesn't improve its profitability.
The Key Takeaway
While the price-to-earnings ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of earnings expectations.
We've established that Alfresa Holdings maintains its low P/E on the weakness of its forecast for sliding earnings, as expected. At this stage investors feel the potential for an improvement in earnings isn't great enough to justify a higher P/E ratio. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.
It is also worth noting that we have found 2 warning signs for Alfresa Holdings that you need to take into consideration.
Of course, you might also be able to find a better stock than Alfresa Holdings. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:2784
Alfresa Holdings
Through its subsidiaries, engages in the manufacture, wholesale, marketing, and import/export of pharmaceuticals, diagnostic reagents, and medical devices/equipment in Japan and internationally.